has been cited by the following article(s):
|
[1]
|
Cardiac substructure dose response after lung cancer radiotherapy
Clinical Lung Cancer,
2026
DOI:10.1016/j.cllc.2026.02.002
|
|
|
|
|
[2]
|
Application of respiratory motion management technology for patients with lung cancer treated with stereotactic body radiotherapy (Review)
Oncology Letters,
2025
DOI:10.3892/ol.2025.15161
|
|
|
|
|
[3]
|
Integration of X-Ray and γ-Ray technologies in lattice radiotherapy: a novel approach for optimizing dose delivery in large-volume non-small cell lung cancer
Radiation Oncology,
2025
DOI:10.1186/s13014-025-02757-x
|
|
|
|
|
[4]
|
Stereotactic boost on residual disease after external-beam irradiation in clinical stage III non-small cell lung cancer: mature results of stereotactic body radiation therapy post radiation therapy (SBRTpostRT) study
La radiologia medica,
2023
DOI:10.1007/s11547-023-01659-w
|
|
|
|
|
[5]
|
Expanded HILUS Trial: A Pooled Analysis of Risk Factors for Toxicity From Stereotactic Body Radiation Therapy of Central and Ultracentral Lung Tumors
International Journal of Radiation Oncology*Biology*Physics,
2023
DOI:10.1016/j.ijrobp.2023.06.246
|
|
|
|
|
[6]
|
Stereotactic Body Radiation Therapy
2023
DOI:10.1007/978-981-99-3978-7_10
|
|
|
|